IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by First Business Financial Services Inc.

First Business Financial Services Inc. raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.7% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,553 shares of the medical research company’s stock after buying an additional 340 shares during the quarter. First Business Financial Services Inc.’s holdings in IQVIA were worth $2,264,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc increased its position in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC acquired a new stake in IQVIA in the second quarter worth about $27,000. Capital Performance Advisors LLP bought a new position in IQVIA in the 3rd quarter valued at about $27,000. Park Place Capital Corp acquired a new position in IQVIA during the 3rd quarter valued at about $28,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA in the 2nd quarter worth approximately $29,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

IQV opened at $202.94 on Friday. The stock has a market cap of $36.83 billion, a PE ratio of 26.63, a P/E/G ratio of 2.17 and a beta of 1.51. IQVIA Holdings Inc. has a 1 year low of $200.20 and a 1 year high of $261.73. The stock’s 50 day simple moving average is $228.86 and its 200-day simple moving average is $228.77. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on IQV. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Friday, November 8th. BTIG Research dropped their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Barclays reduced their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Finally, UBS Group upped their price target on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $259.13.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.